As part of ongoing collaboration with Ark Surgical, ELAFY developed a thought leadership article addressing one of the most critical and evolving topics in gynecologic surgery: tissue dissemination risk in laparoscopic morcellation and the role of containment . Published in Patient Safety & Quality Healthcare (PSQH) , the article reframes containment not solely as a surgical technique, but as a broader institutional governance and risk management decision . The piece explores

By Daniela Schardinger published on Forbes.com After regulatory approval, medtech startups enter a uniquely exposed phase. The product is cleared, years of development are behind them and expectations rise quickly. Boards want validation. Investors want proof of market response. Regulators expect post-market vigilance. Revenue becomes the most visible signal of success. Often, it feels like the only one. This is why many startups move quickly from approval to launch. Not nece

ELAFY authored a feature article for Ark Surgical to be featured in FemTech World examining the hidden clinical, economic, and legal costs of uncontained morcellation — reframing tissue containment as a governance and risk management decision. Read the Featured Article here .

Expert Panel Contribution — Daniela Schardinger Every year, thousands of health tech startups launch with glossy pitches about revolutionsing healthcare. But few stay the course and make the long-term impact that investors and the healthcare system demand. We reached out to Health Tech World and Femtech World members who’ve watched the innovation cycle from every angle with the following question: What’s a hard truth about health innovation that most startups don’t want to

ELAFY supported the creation and launch of ViVac Pharma ’s website, establishing a strong digital presence aligned with the company’s innovation in the pharmaceutical and life sciences space. The project focused on developing clear positioning, refining messaging, and building a platform that communicates both the scientific foundation and strategic vision of the company to key stakeholders. The website serves as a foundation for ongoing visibility, investor communication, a

Interview with Daniela Schardinger on Health Tech World : On Innovation, Systems Change and the Real Cost of Progress Q: Your career spans startups, global health initiatives, and emerging tech. What’s the common thread that’s guided your journey? A: Curiosity and a commitment to solving real problems. Whether I’ve been working with a scrappy startup or sitting at a global policy table, the throughline is the same: identifying overlooked needs and finding practical, scalable